Claims:

1. A method of preparing an antibody pharmaceutical formulation having a viscosity of 10 cP or less comprising during an ultrafiltration/diafiltration step buffer exchanging a composition comprising the antibody with a diafiltration buffer comprising at least 20 mM calcium acetate at a temperature greater than 30°C.

2. The method of claim 1, wherein the composition comprises the antibody at a concentration of at least 90 mg/mL.

3. The method of claim 1, wherein the composition comprises the antibody at a concentration of at least 120 mg/mL.

4. The method of any one of claims 1-3, wherein the exchanging step occurs at a temperature between 30°C and 40°C.

5. The method of any one of claims 1-4, wherein the exchanging step occurs at a temperature greater than 35°C.

6. The method of any one of claims 1-5, wherein the exchanging step occurs at 37°C.

7. The method of claim 9, wherein the diafiltration buffer comprises 23 mM calcium acetate.

8. The method of any one of claims 1-7, wherein the diafiltration buffer further comprises a polyol.

9. The method of claim 8, wherein the polyol is sucrose.

10. The method of claim 9, wherein diafiltration buffer comprises sucrose present at a concentration of 1% to 15%.

11. The method of claim 9, wherein the diafiltration buffer comprises sucrose at a concentration of about 7%.

12. The method of any one of claims 1-11, further comprising the step of filtering the pharmaceutical formulation.

13. The method of any one of claims 1-12, further comprising the step of aliquoting the pharmaceutical formulation into a drug product form.

14. The method of any one of claims 1-13, wherein the antibody is romosozumab, abciximab, adalimumab, alemtuzumab, basiliximab, belimumab, bevacizumab, brentuximab vedotin, canakinumab, cetuximab, certolizumab pegol, daclizumab, denosumab, eculizumab, efalizumab, gemtuzumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, nivolumab, ofatumumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tocilizumab, tositumomab, trastuzumab or ustekinumab, vedolizumab.

15. The method of any one of claims 1-14, wherein the pharmaceutical formulation after the exchanging step comprises at least 50 mM acetate and 12 mM calcium.